CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Smart Money VCs (6327) Pharma Startups (4743)
Targacept is a biopharmaceutical company advancing NNR Therapeutics for the treatment of various diseases and disorders. The company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout...Show all
Company (IPO / Went public)
Phone: 336-480-2100
100 North Main Street
Suite 1510
Winston-Salem, 27101
North Carolina, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Targacept | $123.5M | Apr 13, 2006 |
| Integral Molecular | $0.5M | Dec 18, 2013 |
| Peptimmune | $83.6M | Mar 24, 2011 |
| See all 16 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Name | Firm |
|---|---|
| Login to see details | Burrill & Company |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Exo-s-mecamylamine formulation and use in treatment | Mar 12, 2014 | Mar 14, 2017 | Patent |
| Nicotinic receptor non-competitive antagonists | Aug 27, 2015 | Jan 03, 2017 | Patent |
| Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide | Oct 20, 2014 | Nov 03, 2015 | Patent |
| Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3ylvinyl)pyrimidine | Nov 07, 2013 | Sep 29, 2015 | Patent |
| Hydroxybenzoate salts of metanicotine compounds | Jun 05, 2014 | Aug 18, 2015 | Patent |
